Type stringclasses 2
values | Section_id stringclasses 4
values | Primary_id stringlengths 11 11 | Secondary_id stringlengths 0 11 | Statement stringlengths 34 385 | Label stringclasses 2
values | Primary_evidence_index sequencelengths 1 65 | Secondary_evidence_index sequencelengths 0 73 | Primary_ct stringlengths 1.11k 16.3k | Secondary_ct stringlengths 101 16.3k | __index_level_0__ stringlengths 36 36 |
|---|---|---|---|---|---|---|---|---|---|---|
Comparison | Intervention | NCT01928186 | NCT00684983 | All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01928186', 'Intervention': ['INTERVENTION 1: ', ' Diagnostic (FLT PET)', ' Patients with early stage, ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment. The surgery follows 1-7 days after the second FLT PET scan.'... | {'Clinical Trial ID': 'NCT00684983', 'Intervention': ['INTERVENTION 1: ', ' Arm A', ' Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. lapatinib ditosylate: Gi... | 5bc844fc-e852-4270-bfaf-36ea9eface3d |
Single | Eligibility | NCT00662129 | Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | Contradiction | [
18,
22,
23,
24
] | [] | {'Clinical Trial ID': 'NCT00662129', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel + Gemcitabine + Bevacizumab', ' Patients receive 125 mg/m^2 paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and 1000 mg/m^2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and 15 mg/kg bevaci... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 86b7cb3d-6186-4a04-9aa6-b174ab764eed | |
Comparison | Adverse Events | NCT00093145 | NCT00703326 | Heart-related adverse events were recorded in both the primary trial and the secondary trial. | Entailment | [
0,
3
] | [
0,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00093145', 'Intervention': ['INTERVENTION 1: ', ' Albumin-bound Paclitaxel, Carboplatin + Herceptin', ' Participants received albumin-bound paclitaxel, 100 mg/m^2 weekly every 3 out of 4 weeks, carboplatin at an area under the curve (AUC) = 6 every 4 weeks and Herceptin weekly, 4 mg/kg the f... | {'Clinical Trial ID': 'NCT00703326', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab (IMC-1121B) + Docetaxel', ' Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.', ' Docetaxel is administered at a dose of 75 mil... | dbed5471-c2fc-45b5-b26f-430c9fa37a37 |
Single | Eligibility | NCT01097642 | Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | Contradiction | [
0,
1,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT01097642', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone', ' Brand name is Ixempra ®; it is an epothilone B analog used in combination with other chemotherapeutics against cancer.', ' Ixabepilone: Ixabepilone will be given at 40mg/m^2 IV over 180 minutes on day 1 of each of four 21 day... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 20c35c89-8d23-4be3-b603-ac0ee0f3b4de | |
Comparison | Intervention | NCT00852930 | NCT02308020 | Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT00852930', 'Intervention': ['INTERVENTION 1: ', ' Laser Therapy Alone', ' therapist administered laser treatment', ' laser: therapist administered laser', 'INTERVENTION 2: ', ' Mld Alone', ' therapist administered manual lymphatic drainage', ' manual lymphatic drainage: therapist adminis... | {'Clinical Trial ID': 'NCT02308020', 'Intervention': ['INTERVENTION 1: ', ' Part A Abemaciclib: HR+, HER2+ Breast Cancer', ' Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants wit... | f17cb242-419d-4f5d-bfa4-41494ed5ac0e |
Comparison | Eligibility | NCT00971945 | NCT01027416 | Patients must have already participated in a specific clinical study to participate in the primary trial or the secondary trial. | Contradiction | [
0,
1
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24
] | {'Clinical Trial ID': 'NCT00971945', 'Intervention': ['INTERVENTION 1: ', ' Treatment Arm', ' Paclitaxel 100 mg/m2 IV administered on Days 1, 8, 15, 22, 29, 36 and then suspended until Day 49 (1 course comprised of 49 days).'], 'Eligibility': ['Inclusion Criteria:', ' Subjects who were confirmed to have a response a... | {'Clinical Trial ID': 'NCT01027416', 'Intervention': ['INTERVENTION 1: ', ' No Intervention', ' No Intervention: Standard of care', 'INTERVENTION 2: ', ' Tamoxifen', ' Tamoxifen 20 mg orally 1x/day for 4 weeks', ' Tamoxifen: Drug: Tamoxifen 20 mg orally 1x/day for 4 weeks'], 'Eligibility': ['Inclusion Criteria:', ... | fc5c4554-7ce9-4c16-b374-a3cd9d15b021 |
Single | Eligibility | NCT00633750 | Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for the primary trial. | Contradiction | [
0,
1,
4,
10
] | [] | {'Clinical Trial ID': 'NCT00633750', 'Intervention': ['INTERVENTION 1: ', ' Tarceva', ' Following a pre-treatment core breast biopsy, participants are given Tarceva at a dose of 150 mg/day by mouth for 5-14 days. Within 24 hours of their last dose of Tarceva, participants undergo a post-treatment resection of their t... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 96b77cdd-aa9f-4770-8447-8a04d9ca5da7 | |
Comparison | Intervention | NCT00003404 | NCT00711529 | the primary trial and the secondary trial have Hypnotherapy based interventions, the secondary trial also used pain medication in its intervention. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00003404', 'Intervention': ['INTERVENTION 1: ', ' Adjuvant Radiotherapy', ' Adjuvant radiation was started within 12 weeks of local excision or breast re-excision.', ' Adjuvant Radiotherapy: Adjuvant radiation therapy'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically proven p... | {'Clinical Trial ID': 'NCT00711529', 'Intervention': ['INTERVENTION 1: ', ' Hypnotherapy', ' Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. Patients will also be instructed on the use of sel... | c73faed2-371b-4238-bf7d-293fae380203 |
Single | Eligibility | NCT00201773 | Adele is an 85 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she is eligible for the primary trial | Entailment | [
0,
1,
2,
3,
4,
6
] | [] | {'Clinical Trial ID': 'NCT00201773', 'Intervention': ['INTERVENTION 1: ', ' Exemestane + Celecoxib', ' Exemestane + celecoxib (16 weeks) vs. Baseline', 'INTERVENTION 2: ', ' Exemestane', ' Exemestane (8 weeks) vs. Baseline'], 'Eligibility': ['Inclusion Criteria:', ' Must be female with histologically confirmed bre... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8765009d-ffc4-4395-ab7a-11ecdfd43a40 | |
Comparison | Intervention | NCT02606708 | NCT02504424 | Only patients in the primary trial receive 40.5 Gy of brachytherapy, patients in the secondary trial receive no radiotherapy whatsoever. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02606708', 'Intervention': ['INTERVENTION 1: ', ' Accelerated Intensity Modulated Radiation Therapy (AIMRT)', ' All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IM... | {'Clinical Trial ID': 'NCT02504424', 'Intervention': ['INTERVENTION 1: ', ' AeroForm Tissue Expander', ' AeroForm Tissue Expansion inflation with carbon dioxide by remote control', ' AeroForm Tissue Expander: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by rem... | 0ad7293d-df35-42e8-881d-f2afc3f7d3fd |
Single | Eligibility | NCT00895414 | Certain drinks are banned for patients undertaking the primary trial. | Entailment | [
0,
8
] | [] | {'Clinical Trial ID': 'NCT00895414', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin Hydrochloride Alone', ' Participants who received doxorubicin hydrochloride alone in either Cycle 1 or Cycle 2.', 'INTERVENTION 2: ', ' Doxorubicin Hydrochloride With Enalapril', ' Participants who received doxorubicin hydrochlo... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2bc1e094-41a1-46d9-9b0c-b5a47f23323d | |
Single | Adverse Events | NCT00777049 | Most of the cases of CHF in the primary trial, were in cohort 1. | Entailment | [
0,
6,
14,
20
] | [] | {'Clinical Trial ID': 'NCT00777049', 'Intervention': ['INTERVENTION 1: ', ' ER+ and/or PgR+ (Arm I)', ' Panobinostat - LBH589: hard gelatine capsule - 5mg and 20mg', 'INTERVENTION 2: ', ' ER- and PgR- (Arm II)', ' Panobinostat - LBH589: hard gelatine capsule - 5mg and 20mg'], 'Eligibility': ['Inclusion Criteria:', ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 83b83400-1439-462d-bba3-42817b5b1fa1 | |
Single | Eligibility | NCT00058058 | Candidates for the primary trial must have a life expectancy over 6 months. | Contradiction | [
19,
9
] | [] | {'Clinical Trial ID': 'NCT00058058', 'Intervention': ['INTERVENTION 1: ', ' Reference Standard Positive (RS+)', ' Reference Standard Positive indicates a breast cancer diagnosed in the contralateral (study) breast. Participants who received a diagnosis of ductal carcinoma in situ or any invasive breast cancer as a re... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c3257f7b-f5b4-4a9c-8a8f-b037f27caa8f | |
Single | Eligibility | NCT02964234 | Patients eligible for the primary trial must live in the USA. | Entailment | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT02964234', 'Intervention': ['INTERVENTION 1: ', ' Empowerment', ' Behavior: Empowerment', ' Empowerment: Three group sessions (breast cancer education; communication; volunteerism) 1.5 hours 3 times across 3 weeks', 'INTERVENTION 2: ', ' Education', ' Behavior: Education', ' Education: T... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 17a821f8-5e68-4bf7-ac01-3f96ddfc5187 | |
Comparison | Intervention | NCT02525718 | NCT02606708 | Patients in group 1 of the secondary trial and the primary trial do not receive the same dosage of AIMRT. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02525718', 'Intervention': ['INTERVENTION 1: ', ' Placebo', ' Subjects will be randomly selected to receive saline (placebo), administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery.', ' Saline: If randomized to this arm, subjects will rece... | {'Clinical Trial ID': 'NCT02606708', 'Intervention': ['INTERVENTION 1: ', ' Accelerated Intensity Modulated Radiation Therapy (AIMRT)', ' All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IM... | d76d6c7f-ba39-483c-a89e-152af5ae2878 |
Comparison | Intervention | NCT01669343 | NCT00146172 | the primary trial administers letrozole for 28 days, whereas the secondary trial administers is intervention over 4 cycles of 21 days. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01669343', 'Intervention': ['INTERVENTION 1: ', ' Post-menopausal Women Using Adjuvant Letrozole', ' Part A Routine Care Letrozole; Part B Double Dose Letrozole in overweight/obese participants', ' Letrozole: Part A Monitor standard of care letrozole use for 28 days; measure blood levels of... | {'Clinical Trial ID': 'NCT00146172', 'Intervention': ['INTERVENTION 1: ', ' Neratinib 40 mg', 'Neratinb 40 mg qd', 'INTERVENTION 2: ', ' Neratinib 80 mg', 'Neratinib 80 mg qd'], 'Eligibility': ['Inclusion Criteria:', ' Her2/neu or Her1/EGFR positive cancer', ' Eastern Cooperative Oncology Group (ECOG) performance s... | 65f3e755-3e23-4e84-a218-87922759094d |
Single | Eligibility | NCT00952692 | Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
41,
42,
43,
44,
45,
46,
47,
48,
49,
50,
51,
52,
53,
54... | [] | {'Clinical Trial ID': 'NCT00952692', 'Intervention': ['INTERVENTION 1: ', ' dHER2 + AS15 ASCI + Lapatinib', ' Patients will receive dHER2 ASCI injections IM every 2 weeks for 2 cycles . In between cycles there is 4 weeks without vaccine. The daily dose of lapatinib is 5 tablets (1250 mg of lapatinib) taken orally at ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d3590771-806b-4754-a455-38113bfedfca | |
Comparison | Intervention | NCT00994279 | NCT00545077 | both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00994279', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: Yoga Intervention', ' Yoga Intervention', ' Yoga: Yoga sessions', 'INTERVENTION 2: ', ' Arm 2: Educational Wellness Group', ' Educational Wellness Group', ' Education: Educational Wellness Group'], 'Eligibility': ['Inclusion Criter... | {'Clinical Trial ID': 'NCT00545077', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Endocrine Therapy (ET)', ' Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. T... | 941b960f-8d57-4830-9d4c-8e96765ba76c |
Comparison | Intervention | NCT01425268 | NCT01373671 | CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01425268', 'Intervention': ['INTERVENTION 1: ', ' AeroForm Tissue Expansion', ' AeroForm Tissue Expansion inflation with carbon dioxide by remote control', ' AeroForm Tissue Expansion: The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy... | {'Clinical Trial ID': 'NCT01373671', 'Intervention': ['INTERVENTION 1: ', ' FFDM and DBT', ' FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration', 'INTERVENTION 2: ', ' FFDM Only', 'FFDM exam only'], 'Eligibility': ['Inclusion Criteria:', ' All subjects enrolled into the collection study must:', ' Provide signe... | f79a9011-0a68-4255-a40f-5d73af412bf0 |
Comparison | Adverse Events | NCT00777101 | NCT00559845 | There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00777101', 'Intervention': ['INTERVENTION 1: ', ' Neratinib', ' Neratinib', ' Neratinib: Tablets, 240mg once per day until disease progression or unacceptable toxicity', 'INTERVENTION 2: ', ' Lapatinib+Capecitabine', ' Lapatinib plus Capecitabine', ' Lapatinib: Tablets 1250mg once per da... | {'Clinical Trial ID': 'NCT00559845', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab', ' FEC, followed by paclitaxel, given concomitantly with bevacizumab for approximately 3-12 months.', ' FEC: 5-Fluorouracil 600 mg/m^2 i.v. bolus over 15 min; epirubicin 90 mg/m^2 i.v. infusion over 1 hour; cyclophosphamide 600 ... | 1b4f8828-cc7f-4831-a1c0-cc14e6ad23af |
Comparison | Intervention | NCT00075270 | NCT01781299 | the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing a physcotherapy course. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT00075270', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib With Paclitaxel', ' Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the course of 3 hours, every 3 weeks. The treatment group was strati... | {'Clinical Trial ID': 'NCT01781299', 'Intervention': ['INTERVENTION 1: ', ' AlloDerm RTU', ' Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement.', 'AlloDerm RTU', 'INTERVENTION 2: ', ' SurgiMend PRS', ' Participants within this arm will... | 57f3a264-9119-4931-9f9c-9cb20e945973 |
Single | Results | NCT00305448 | At least 4 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR). | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | [] | {'Clinical Trial ID': 'NCT00305448', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant 250 mg', 'Fulvestrant 250 mg', 'INTERVENTION 2: ', ' Fulvestrant 250 mg + Loading Dose', ' Fulvestrant 250 mg + Loading Dose'], 'Eligibility': ['Inclusion Criteria:', ' Breast Cancer has continued to grow after having received t... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 589e2f5b-9286-465b-8162-bb1549cd5ece | |
Single | Adverse Events | NCT03066947 | Less than 1/4 patients in the primary trial experienced adverse events. | Contradiction | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT03066947', 'Intervention': ['INTERVENTION 1: ', ' SV-BR-1-GM Monotherapy', ' Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alph... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8275f846-59b6-404d-a6d8-e01335279f1a | |
Single | Intervention | NCT01390064 | The both Cohorts of the primary trial receive their treatment via Subcutaneous administration. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [] | {'Clinical Trial ID': 'NCT01390064', 'Intervention': ['INTERVENTION 1: ', ' Initial Cohort', ' Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms', ' Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimoto... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b3c1f5d1-6f7f-4bab-a4e8-5d1dab597cc7 | |
Single | Eligibility | NCT01142661 | the primary trial does not accept patients with grade 1 alopecia. | Entailment | [
17,
19
] | [] | {'Clinical Trial ID': 'NCT01142661', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate', 'Eribulin Mesylate : Eribulin Mesylate: A dose of 1.4 mg/m^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death.'], 'Eligibility': ['Inclusion Crite... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 18d9991c-ca96-4bab-93af-77654857a07f |
End of preview. Expand in Data Studio
- Downloads last month
- 45